Released Nov 5, 2015, after the close
10-Q filed Nov 9, 2015, 40 days after period end · 0001019687-15-003962
Q3 2015 · 10-Q
Revenue$6.08M$6.08M +1.2% vs Q3 2014−1.8% vs Q2 2015
Net Income-$1.35M-$1.35M N/M vs Q3 2014N/M vs Q2 2015
EPS Diluted-$0.73-$0.73 N/M vs Q3 2014N/M vs Q2 2015
Operating Income-$1,314,000N/M
Operating Cash Flowderived-$1,088,000N/M
Free Cash Flowderived-$1,424,000N/M
Margins · derived
Operating margin-21.6%−0.4 pt vs Q3 2014
Net margin-22.2%−0.3 pt vs Q3 2014
What the release said
The release
Same quarter
| Metric | Q3 2015 | Q3 2014 | Q3 2013 | Q3 2012 |
|---|---|---|---|---|
| Revenue | $6.08M | $6.01M | $5.53M | $6.05M |
| Net Income | -$1.35M | -$1.32M | -$234.00K | $54.00K |
| EPS Diluted | -$0.73 | -$0.01 | $0.00 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR